JBO—Launched and flying ahead  by Coleman, Robert & Hadji, Peyman
Journal of Bone Oncology 2 (2013) 1Contents lists available at ScienceDirectJournal of Bone Oncology2212-13
(http://c
http://djournal homepage: www.elsevier.com/locate/jboEditorialJBO—Launched and ﬂying aheadWelcome to volume two of the Journal of Bone Oncology, the
ﬁrst journal devoted to the multidisciplinary management of
bone disease in cancer patients. During the past year, the
importance of bone oncology in cancer care has continued to
increase. This follows the emergence of further clinical data
supporting the use of bone targeted treatments in the adjuvant
treatment of early breast cancer [1,2], the activity of denosumab
in delaying the development of bone metastases in castrate
resistant prostate cancer [3] and clearer understanding of the
risk beneﬁts of denosumab in the prevention of skeletal morbidity
in advanced cancer patients with bone metastases. [4,5] Along-
side these important clinical trial results that are already inﬂuen-
cing clinical practice, our understanding of the importance of the
bone microenvironment and the numerous cellular interactions
that take place in the process of metastasis as well as the concept
of tumour dormancy has expanded further [6,7].
We are very excited by the achievements of the journal during this
ﬁrst year, both in terms of the number and quality of manuscripts
received. An excellent and unique mix of preclinical science and
clinical research in bone oncology has been addressed.
So far we have received 38 manuscripts and to date accepted 25.
Of the accepted manuscripts, 13 of these were original manuscripts
and 9 were reviews, supplemented by two case reports and one
editorial. All three issues in volume one have been published on
schedule. The high proportion of original manuscripts is particularly
gratifying for a new journal and will greatly assist in developing a
successful application to Medline later this year, the ﬁrst critical step
to negotiate in order to establish an impact factor and the long term
viability of the journal.
We are extremely grateful to both our outstanding interna-
tional Editorial Board who have helped promote the journal and
encourage submission of high quality manuscripts and to Elsevier
who have ensured the journal has achieved high visibility through
Science Direct and provided a wonderfully efﬁcient publication74/$ - see front matter & 2015 Published by Elsevier GmbH. This is an open ac
reativecommons.org/licenses/by-nc-nd/4.0/).
x.doi.org/10.1016/j.jbo.2013.02.002process. This has enabled us on average to review and publish
accepted manuscripts within 3 months, providing authors with a
rapid route to disseminating their research results. The future for
Journal of Bone Oncology is bright and we hope you ﬁnd the
publication informative and relevant. We look forward to receiv-
ing your contributions to the Journal.
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